ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,508Medicare Part D Prescriptions Filled, Including Refills

Rank: 1328 out of 3647

$695K Total Retail Price of All Prescriptions

Rank: 569 out of 3647

505 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

25% of this provider’s 505 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

9% of this provider’s 505 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

2% of this provider’s 4,553 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$93 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
AMLODIPINE BESYLATE 242 167 1 2
SIMVASTATIN 215 151 2 1
LISINOPRIL 190 100 3 4
FUROSEMIDE 158 98 4 8
OMEPRAZOLE 148 118 5 3
OXYCODONE HCL 143 14 S2 6 75
METFORMIN HCL 141 76 7 6
WARFARIN SODIUM 138 90 8 15
METOPROLOL TARTRATE 117 100 9 7
HYDROCHLOROTHIAZIDE 105 74 10 9
OXYCODONE-ACETAMINOPHEN 93 64 S2 11 91
CLOPIDOGREL 88 67 12 26
CITALOPRAM HBR 86 60 13 25
LEVOTHYROXINE SODIUM 82 55 14 5
ZOLPIDEM TARTRATE 82 44 14 14
FAMOTIDINE 81 55 16 61
PREDNISONE 78 56 17 43
HYDROCODONE-ACETAMINOPHEN 77 33 S3 18 12
OXYCODONE HCL-ACETAMINOPHEN 76 0 S2 19 104
GABAPENTIN 75 43 20 17
ALPRAZOLAM 73 46 21 31
IBUPROFEN 72 12 22 55
DIOVAN 68 53 23 40
QUETIAPINE FUMARATE 68 59 23 89
AZITHROMYCIN 68 46 23 34
CYCLOBENZAPRINE HCL 65 17 R 26 98
POTASSIUM CHLORIDE 62 29 27 24
DONEPEZIL HCL 61 49 28 30
GLIPIZIDE 61 43 28 41
CARVEDILOL 60 46 30 20
TRAMADOL HCL 60 40 30 22
ENALAPRIL MALEATE 59 47 32 35
NOVOLIN R 59 50 32 139
ADVAIR DISKUS 59 29 32 52
ATENOLOL 59 41 32 10
CLONIDINE HCL 58 30 36 46
ENDOCET 57 13 S2 37 269
METOPROLOL SUCCINATE 55 40 38 18
SERTRALINE HCL 53 37 39 27
LEVETIRACETAM 53 34 39 122
NOVOLIN 70-30 53 28 39 130
NEXIUM 53 24 39 44
PLAVIX 53 40 39 39
GLYBURIDE 52 24 R 44 54
TAMSULOSIN HCL 51 37 45 28
DIGOXIN 51 39 45 51
ALBUTEROL SULFATE 51 45 45 157
METHYLPREDNISOLONE 51 36 45 78
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 5, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.